Gilert Ariel, Machluf Marcelle
Faculty of Biotechnology and Food Engineering, Technion Israel Institute of Technology, Haifa, Israel.
J Angiogenes Res. 2010 Oct 8;2(1):20. doi: 10.1186/2040-2384-2-20.
Treating brain tumors using inhibitors of angiogenesis is extensively researched and tested in clinical trials. Although anti-angiogenic treatment holds a great potential for treating primary and secondary brain tumors, no clinical treatment is currently approved for brain tumor patients. One of the main hurdles in treating brain tumors is the blood brain barrier - a protective barrier of the brain, which prevents drugs from entering the brain parenchyma. As most therapeutics are excluded from the brain there is an urgent need to develop delivery platforms which will bypass such hurdles and enable the delivery of anti-angiogenic drugs into the tumor bed. Such delivery systems should be able to control release the drug or a combination of drugs at a therapeutic level for the desired time. In this mini-review we will discuss the latest improvements in nano and micro drug delivery platforms that were designed to deliver inhibitors of angiogenesis to the brain.
使用血管生成抑制剂治疗脑肿瘤已在临床试验中得到广泛研究和测试。尽管抗血管生成治疗在治疗原发性和继发性脑肿瘤方面具有巨大潜力,但目前尚无针对脑肿瘤患者的临床治疗方法获得批准。治疗脑肿瘤的主要障碍之一是血脑屏障——大脑的一种保护屏障,它阻止药物进入脑实质。由于大多数治疗药物被排除在脑外,迫切需要开发能够绕过此类障碍并将抗血管生成药物输送到肿瘤床的递送平台。此类递送系统应能够在所需时间内以治疗水平控制药物或药物组合的释放。在本综述中,我们将讨论旨在将血管生成抑制剂输送到大脑的纳米和微米药物递送平台的最新进展。